Cardinal health Inc (NYSE:). the stock hit an unprecedented high, touching an all-time high of $126.3. According to InvestingPro analysis, the stock remains undervalued despite this milestone, highlighting the company’s robust performance amid a challenging healthcare environment. With a market capitalization of $30.5 billion, Cardinal Health has established itself as a prominent player in the healthcare sector. Over the past year, Cardinal Health has witnessed a significant increase in its stock value, with an impressive increase of 19.61%, including an incredible gain of 31.87% over the past six months. Investors have shown growing confidence in the company’s strategic initiatives and its ability to deal with market fluctuations, lifting the stock to new heights. EXCELLENT rating of the company’s financial health at InvestingPro further confirms this momentum. Achieving this all-time record serves as a testament to Cardinal Health’s enduring strength and potential for continued growth in the competitive healthcare sector. The company’s commitment to shareholder value is evidenced by its 43-year track record of consecutive dividend payments, demonstrating exceptional stability in a dynamic healthcare market.
In other recent news, Cardinal Health raised its full-year earnings guidance for fiscal 2025, driven primarily by strength within Pharmaceutical (TADAWUL:) and the Specialty Solutions segment. The company now expects its non-GAAP EPS to be at the higher end of its previously projected range of $7.75 to $7.90. Cardinal Health also announced plans to acquire Integrated Oncology Network for $1.1 billion and plans to acquire majority stakes in The GI Alliance Holdings, LLC, and Advanced Diabetes Supply Group. The company successfully raised $2.9 billion through a public offering of senior notes to partially finance those acquisitions.
TD Cowen upgraded shares of Cardinal Health from Hold to Buy, with a new target price of $144. The upgrade is based on the expectation that Cardinal Health will beat current earnings projections due to new client acquisitions, strong utilization trends and recent mergers and acquisitions in specialty services. Evercore ISI upgraded its rating on shares of Cardinal Health from In Line to Outperform, suggesting the potential for higher long-term guidance. BofA Securities also upgraded Cardinal Health stock from Neutral to Buy, raising its price target to $145, expecting an increase in EPS estimates.
Finally, T2 Biosystems (NASDAQ: ) decided to license its sepsis detection technology after a commercial agreement with Cardinal Health, with the goal of improving patient outcomes, reducing mortality and lower healthcare costs by enabling faster, targeted antimicrobial decisions. These are all recent developments that highlight Cardinal Health’s continued growth and strategic initiatives.
This article was generated with the help of AI and reviewed by an editor. See our T&C for more information.
